glp-1 ra drugs Comparing Ozempic, Wegovy and Other Evolution of GLP‐1 Receptor Agonists

The North Carolina State Health Plan provides a striking example of the financial implications involved, estimating that continuing to cover brand GLP-1s for weight loss in 2024 would require increasing premiums by $48.50 per subscriber per month for all members, not just GLP-1 users

Curr Pharm Des (2021)

Fast acting insulin aspart

Before we start looking ahead, we want to take stock of where 2024 left the AOM market

In 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% over a mean 39.8-month follow-up

In contrast, a pharmacological substrate is cleaved by DPP-4 ex vivo, but evidence for cleavage of the endogenous peptide in vivo may be lacking (e.g., aprotinin, BNP, -casomorphin, chorionic gonadotrophin, endomorphin-1, endomorphin-2, enterostatin, eotaxin, erythropoietin, GCSF [granulocyte colony stimulating factor], and many others)